Supreme Court Fish Oil Case Could Slow Generic Drug Competition and Raise Patient Costs

What Happened

The Supreme Court is hearing Hikma v. Amarin, a case that could fundamentally reshape how generic drugmakers bring cheaper medications to market. The dispute centers on "skinny labeling," a regulatory strategy that allows generic manufacturers to sell copycat drugs for unpatented uses while a brand-name company still holds patents on other uses of the same medication.

The specific case involves Vascepa, a fish oil-based drug made by Amarin for heart disease patients. After Amarin's patent expired for one patient group, generic maker Hikma sought FDA approval to sell a cheaper version—but only for that unpatented use. Amarin sued, arguing that Hikma's marketing descriptions (like calling it a "generic version of Vascepa") would encourage doctors to prescribe it for the still-patented use, infringing their patent rights. A federal appeals court sided with Amarin, but Hikma appealed to the Supreme Court. (Read the full NPR article.)

Why This Matters for the Common Good

This case strikes at the heart of pharmaceutical affordability—a central concern for Americans paying some of the highest drug prices globally. The outcome could determine whether generic competition reaches patients quickly or faces legal paralysis.

The Numbers: Generic drugs now account for 9 out of 10 prescriptions filled in America, and Americans pay less for generics than patients in any other developed nation. Yet the NPR article cites research showing that skinny labeling alone saved Medicare $15 billion between 2015 and 2021—demonstrating the enormous cost-control value of this pathway. If the Supreme Court restricts skinny labeling, that cost-saving mechanism disappears, and patients face longer waits for affordable alternatives.

Connection to CGP Policy

Healthcare: The CGP position—"You keep your doctor. You keep your hospital. The only thing that changes is who pays the bill"—emphasizes affordability and access without disrupting patient choice. Skinny labeling embodies this principle: patients maintain access to the same medications, but generic competition drives down costs. A Supreme Court decision limiting skinny labeling would directly undermine cost containment for Medicare and private insurance beneficiaries.

SCOTUS Reform: This case also illustrates why CGP advocates for Supreme Court reform. Patent law decisions made by unelected justices have enormous downstream effects on healthcare costs and patient access. The fact that 70+ legal scholars and the Trump administration's solicitor general sided with the generic maker—yet a federal court still ruled against them—shows how judicial ideology can override expert consensus on public policy outcomes.